Notes
The study was funded by Sanofi China.
Reference
Qin S, et al. Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. Cost Effectiveness and Resource Allocation : 4 Aug 2018. Available from: URL: https://resource-allocation.biomedcentral.com/articles/10.1186/s12962-018-0112-0
Rights and permissions
About this article
Cite this article
FOLFOX4 more effective, less costly in hepatocellular carcinoma. PharmacoEcon Outcomes News 810, 13 (2018). https://doi.org/10.1007/s40274-018-5204-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5204-8